Inmed Pharmaceuticals Inc (IMLFF) 0.0750 $IMLFF
InMed Announces Appointment of Eric A. Adams as CEO, President and Director
Marketwire Canada - Thu Jun 16, 8:03AM CDT
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 16, 2016) - InMed Pharmaceuticals Inc. ("InMed" or "the Company"
(CSE:IN)(OTCQB:IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies, is pleased to announce today the appointment of Mr. Eric A. Adams as CEO, President and as a member of the Board of Directors. Mr. Adams is a seasoned biopharmaceutical executive with over 25 years' experience in company and capital formation, global market development, mergers & acquisitions, licensing and corporate governance.
Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market - Global Pipeline Review, H2 2015
M2 - Mon Feb 08, 11:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/s368wq/chronic) has announced the addition of the "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Chronic Obstructive Pulmonary Disease (COPD) Overview - Therapeutics Development - Pipeline Products for Chronic Obstructive Pulmonary Disease (COPD) - Overview - Pipeline Products for Chronic Obstructive Pulmonary Disease (COPD) - Comparative Analysis - Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics under Development by Companies - Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics under Investigation by Universities/Institutes - Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Chronic Obstructive Pulmonary Disease (COPD) - Products under Development by Companies - Chronic Obstructive Pulmonary Disease (COPD) - Products under Investigation by Universities/Institutes - Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - AlgiPharma AS - C4X Discovery Limited - Carolus Therapeutics, Inc. - Cellular Biomedicine Group, Inc. - Chiesi Farmaceutici SpA - Circassia Pharmaceuticals Plc - Hydra Biosciences, Inc. - iCeutica, Inc. - InMed Pharmaceuticals Inc. - Innate Pharma SA - Invion Limited - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Johnson & Johnson - Nostrum Pharmaceuticals, LLC - Novabiotics Limited - Novartis AG - OPKO Health, Inc. - Quark Pharmaceuticals, Inc. - Re-Pharm Limited - Recipharm AB - Respira Therapeutics, Inc. - Respiratorius AB - rEVO Biologics, Inc. - Seoul Pharma Co., Ltd. - SkyePharma Plc - Spring Bank Pharmaceuticals, Inc. - Stelic Institute & Co. - sterna biologicals Gmbh & Co KG - Sucampo Pharmaceuticals, Inc. - Sunovion Pharmaceuticals Inc. - Synovo GmbH - Syntrix Biosystems, Inc. - Yuhan Corporation - Yungjin Pharm. Co., Ltd. - Zambon Company S.p.A. For more information visit http://www.researchandmarkets.com/research/s368wq/chronic
JNJ: 119.92 (-0.80), OPK: 9.83 (-0.03), SCMP: 11.31 (-0.11), RBIO: (), CBMG: 14.07 (-0.21), NVS: 81.34 (-0.60)
Glaucoma - Pipeline Review - Comparative Analysis, Therapeutics Assessment, Mechanism of Action & Route of Administration
M2 - Fri Jan 29, 5:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/7v2mrr/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - AC Immune SA - Acadia Pharmaceuticals Inc. - Advanced Refractive Technologies, Inc. - Aerie Pharmaceuticals, Inc. - Allergan Plc - Altacor Limited - Amakem NV - Asahi Kasei Pharma Corp. - AUS Bio Limited - Bausch & Lomb Incorporated - Bionure Farma, S.L. - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - China Grand Wuhan General Pharmaceutical Research Institute - D. Western Therapeutics Institute, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Gilead Sciences, Inc. - Glaukos Corporation - GliaCure Inc. - Handok Inc. - Icon Bioscience, Inc. - IMMD Inc. - InMed Pharmaceuticals Inc. - Inotek Pharmaceuticals Corporation - (30 Others) Key Topics Covered: - Introduction - Glaucoma Overview - Therapeutics Development - Pipeline Products for Glaucoma - Overview - Pipeline Products for Glaucoma - Comparative Analysis - Glaucoma - Therapeutics under Development by Companies - Glaucoma - Therapeutics under Investigation by Universities/Institutes - Glaucoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Glaucoma - Products under Development by Companies - Glaucoma - Products under Investigation by Universities/Institutes - Glaucoma - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/7v2mrr/glaucoma
CANF: 2.23 (-0.02), AGN: 253.14 (+0.21), ACAD: 33.64 (+0.37), ITEK: 6.84 (-0.05), GILD: 81.00 (+0.41), GKOS: 30.35 (-1.29), AERI: 19.15 (+0.08), CLBS: 5.45 (-0.02)
InMed Strengthens Board With Appointment of Experienced Biotech Executive Adam Cutler
Marketwired - Mon Nov 23, 5:01AM CST
InMed Pharmaceuticals Inc. ("InMed" (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems is pleased to announce the appointment of Adam Cutler to the Board of Directors.
InMed Pharmaceuticals Inc. Announces Non-Brokered Private Placement - Video News Alert on InvestmentPitch.com
Newsfile Corp - Fri Nov 06, 12:45PM CST
full story)
InMed Provides Update on Progress of Its Development Program for Epidermolysis Bullosa
Marketwired - Wed Nov 04, 4:01AM CST
InMed Pharmaceuticals Inc. ("InMed" (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies would like to provide an update on the progress of INM-750, its lead product in development for epidermolysis bullosa (EB), a serious and severe genetically inherited skin disorder.
InMed Appoints Paul Brennan as President & Chief Executive Officer
Marketwired - Thu Sep 03, 5:00AM CDT
InMed Pharmaceuticals Inc. ("InMed" or "the Company" (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today that Paul Brennan, a 25-year veteran of the life sciences industry, has joined InMed as President & CEO, effective September 14, 2015. Mr. Brennan succeeds Craig Schneider who will remain on the board of directors.
InMed Commences Development of Proprietary Drug Delivery System
Marketwired - Wed Sep 02, 4:01AM CDT
InMed Pharmaceuticals Inc. ("InMed" (CSE: IN)(OTCQB: IMLFF) is pleased to announce it has initiated testing of a novel nanoparticle based delivery system for INM-750 which will be used for clinical formulations. INM-750 is a proprietary phytocannabinoid based compound for the treatment of epidermolysis bullosa simplex (EBS), a rare genetically inherited skin disorder (See NR News Release May 26, 2015 and August 6, 2015).
InMed Appoints Paul Brennan to the Board of Directors
Marketwired - Tue Aug 25, 4:00AM CDT
InMed Pharmaceuticals Inc. ("InMed" or "the Company" (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today the appointment of Paul Brennan to the Company's Board of Directors. Mr. Brennan brings more than 25 years of experience in building, leading and advising top-performing pharmaceutical and biotechnology companies in Europe, Canada and the United States.
ABUS: 3.74 (+0.02), TKMR: 10.83 (+0.58)
InMed Pharmaceuticals Announces Progress in Orofacial Pain Program
Marketwired - Thu Aug 20, 7:01AM CDT
InMed Pharmaceuticals Inc. ("InMed" (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announces today the successful completion and validation of preclinical pain modelling.
InMed Announces Positive In-Vitro Study Results of INM-750 Targeting Epidermolysis Bullosa Simplex (EBS)
Marketwired - Thu Aug 06, 4:01AM CDT
InMed Pharmaceuticals Inc. ("InMed" (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today that it has obtained positive response from its pre-clinical research on INM-750 tested in various in vitro assays. The INM-750 is a proprietary phytocannabinoid based compound for the treatment of epidermolysis bullosa simplex (EBS), a rare genetically inherited skin disorder. INM-750 is designed to modulate skin growth, differentiation and inflammation that are signature characteristics of EBS.
Epidermolysis Bullosa - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jxnlsl/epidermolysis) has announced the addition of the "Epidermolysis Bullosa - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epidermolysis Bullosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epidermolysis Bullosa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Fibrocell Science, Inc. - GlaxoSmithKline plc - InMed Pharmaceuticals Inc. - RegeneRx Biopharmaceuticals, Inc. - Scioderm, Inc. - Shire Plc - TWi Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/jx...dermolysis
FCSC: 1.02 (-0.01), SHPG: 199.82 (+1.22), GSK: 44.16 (-0.33)
Epidermolysis Bullosa Therapeutic Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Thu Jun 25, 8:31PM CDT
The report "Epidermolysis Bullosa - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Epidermolysis Bullosa. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/epidermolysi...eport.html .
SHPG: 199.82 (+1.22), GSK: 44.16 (-0.33)
InMed Announces Appointment of Eric A. Adams as CEO, President and Director
Marketwire Canada - Thu Jun 16, 8:03AM CDT
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 16, 2016) - InMed Pharmaceuticals Inc. ("InMed" or "the Company"
(CSE:IN)(OTCQB:IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies, is pleased to announce today the appointment of Mr. Eric A. Adams as CEO, President and as a member of the Board of Directors. Mr. Adams is a seasoned biopharmaceutical executive with over 25 years' experience in company and capital formation, global market development, mergers & acquisitions, licensing and corporate governance. Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market - Global Pipeline Review, H2 2015
M2 - Mon Feb 08, 11:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/s368wq/chronic) has announced the addition of the "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Chronic Obstructive Pulmonary Disease (COPD) Overview - Therapeutics Development - Pipeline Products for Chronic Obstructive Pulmonary Disease (COPD) - Overview - Pipeline Products for Chronic Obstructive Pulmonary Disease (COPD) - Comparative Analysis - Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics under Development by Companies - Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics under Investigation by Universities/Institutes - Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Chronic Obstructive Pulmonary Disease (COPD) - Products under Development by Companies - Chronic Obstructive Pulmonary Disease (COPD) - Products under Investigation by Universities/Institutes - Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - AlgiPharma AS - C4X Discovery Limited - Carolus Therapeutics, Inc. - Cellular Biomedicine Group, Inc. - Chiesi Farmaceutici SpA - Circassia Pharmaceuticals Plc - Hydra Biosciences, Inc. - iCeutica, Inc. - InMed Pharmaceuticals Inc. - Innate Pharma SA - Invion Limited - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Johnson & Johnson - Nostrum Pharmaceuticals, LLC - Novabiotics Limited - Novartis AG - OPKO Health, Inc. - Quark Pharmaceuticals, Inc. - Re-Pharm Limited - Recipharm AB - Respira Therapeutics, Inc. - Respiratorius AB - rEVO Biologics, Inc. - Seoul Pharma Co., Ltd. - SkyePharma Plc - Spring Bank Pharmaceuticals, Inc. - Stelic Institute & Co. - sterna biologicals Gmbh & Co KG - Sucampo Pharmaceuticals, Inc. - Sunovion Pharmaceuticals Inc. - Synovo GmbH - Syntrix Biosystems, Inc. - Yuhan Corporation - Yungjin Pharm. Co., Ltd. - Zambon Company S.p.A. For more information visit http://www.researchandmarkets.com/research/s368wq/chronic
JNJ: 119.92 (-0.80), OPK: 9.83 (-0.03), SCMP: 11.31 (-0.11), RBIO: (), CBMG: 14.07 (-0.21), NVS: 81.34 (-0.60)
Glaucoma - Pipeline Review - Comparative Analysis, Therapeutics Assessment, Mechanism of Action & Route of Administration
M2 - Fri Jan 29, 5:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/7v2mrr/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - AC Immune SA - Acadia Pharmaceuticals Inc. - Advanced Refractive Technologies, Inc. - Aerie Pharmaceuticals, Inc. - Allergan Plc - Altacor Limited - Amakem NV - Asahi Kasei Pharma Corp. - AUS Bio Limited - Bausch & Lomb Incorporated - Bionure Farma, S.L. - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - China Grand Wuhan General Pharmaceutical Research Institute - D. Western Therapeutics Institute, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Gilead Sciences, Inc. - Glaukos Corporation - GliaCure Inc. - Handok Inc. - Icon Bioscience, Inc. - IMMD Inc. - InMed Pharmaceuticals Inc. - Inotek Pharmaceuticals Corporation - (30 Others) Key Topics Covered: - Introduction - Glaucoma Overview - Therapeutics Development - Pipeline Products for Glaucoma - Overview - Pipeline Products for Glaucoma - Comparative Analysis - Glaucoma - Therapeutics under Development by Companies - Glaucoma - Therapeutics under Investigation by Universities/Institutes - Glaucoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Glaucoma - Products under Development by Companies - Glaucoma - Products under Investigation by Universities/Institutes - Glaucoma - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/7v2mrr/glaucoma
CANF: 2.23 (-0.02), AGN: 253.14 (+0.21), ACAD: 33.64 (+0.37), ITEK: 6.84 (-0.05), GILD: 81.00 (+0.41), GKOS: 30.35 (-1.29), AERI: 19.15 (+0.08), CLBS: 5.45 (-0.02)
InMed Strengthens Board With Appointment of Experienced Biotech Executive Adam Cutler
Marketwired - Mon Nov 23, 5:01AM CST
InMed Pharmaceuticals Inc. ("InMed"
(CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems is pleased to announce the appointment of Adam Cutler to the Board of Directors. InMed Pharmaceuticals Inc. Announces Non-Brokered Private Placement - Video News Alert on InvestmentPitch.com
Newsfile Corp - Fri Nov 06, 12:45PM CST
full story)
InMed Provides Update on Progress of Its Development Program for Epidermolysis Bullosa
Marketwired - Wed Nov 04, 4:01AM CST
InMed Pharmaceuticals Inc. ("InMed"
(CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies would like to provide an update on the progress of INM-750, its lead product in development for epidermolysis bullosa (EB), a serious and severe genetically inherited skin disorder. InMed Appoints Paul Brennan as President & Chief Executive Officer
Marketwired - Thu Sep 03, 5:00AM CDT
InMed Pharmaceuticals Inc. ("InMed" or "the Company"
(CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today that Paul Brennan, a 25-year veteran of the life sciences industry, has joined InMed as President & CEO, effective September 14, 2015. Mr. Brennan succeeds Craig Schneider who will remain on the board of directors. InMed Commences Development of Proprietary Drug Delivery System
Marketwired - Wed Sep 02, 4:01AM CDT
InMed Pharmaceuticals Inc. ("InMed"
(CSE: IN)(OTCQB: IMLFF) is pleased to announce it has initiated testing of a novel nanoparticle based delivery system for INM-750 which will be used for clinical formulations. INM-750 is a proprietary phytocannabinoid based compound for the treatment of epidermolysis bullosa simplex (EBS), a rare genetically inherited skin disorder (See NR News Release May 26, 2015 and August 6, 2015). InMed Appoints Paul Brennan to the Board of Directors
Marketwired - Tue Aug 25, 4:00AM CDT
InMed Pharmaceuticals Inc. ("InMed" or "the Company"
(CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today the appointment of Paul Brennan to the Company's Board of Directors. Mr. Brennan brings more than 25 years of experience in building, leading and advising top-performing pharmaceutical and biotechnology companies in Europe, Canada and the United States. ABUS: 3.74 (+0.02), TKMR: 10.83 (+0.58)
InMed Pharmaceuticals Announces Progress in Orofacial Pain Program
Marketwired - Thu Aug 20, 7:01AM CDT
InMed Pharmaceuticals Inc. ("InMed"
(CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announces today the successful completion and validation of preclinical pain modelling. InMed Announces Positive In-Vitro Study Results of INM-750 Targeting Epidermolysis Bullosa Simplex (EBS)
Marketwired - Thu Aug 06, 4:01AM CDT
InMed Pharmaceuticals Inc. ("InMed"
(CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today that it has obtained positive response from its pre-clinical research on INM-750 tested in various in vitro assays. The INM-750 is a proprietary phytocannabinoid based compound for the treatment of epidermolysis bullosa simplex (EBS), a rare genetically inherited skin disorder. INM-750 is designed to modulate skin growth, differentiation and inflammation that are signature characteristics of EBS. Epidermolysis Bullosa - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jxnlsl/epidermolysis) has announced the addition of the "Epidermolysis Bullosa - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epidermolysis Bullosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epidermolysis Bullosa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Fibrocell Science, Inc. - GlaxoSmithKline plc - InMed Pharmaceuticals Inc. - RegeneRx Biopharmaceuticals, Inc. - Scioderm, Inc. - Shire Plc - TWi Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/jx...dermolysis
FCSC: 1.02 (-0.01), SHPG: 199.82 (+1.22), GSK: 44.16 (-0.33)
Epidermolysis Bullosa Therapeutic Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Thu Jun 25, 8:31PM CDT
The report "Epidermolysis Bullosa - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Epidermolysis Bullosa. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/epidermolysi...eport.html .
SHPG: 199.82 (+1.22), GSK: 44.16 (-0.33)
